Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue

Summary

The progression of neoplasms is frequently associated with thromboembolic complications. Coagulation proteins, particularly tissue factor (TF), have been shown to play a role in tumor growth and metastatic dissemination. TFPI is the principal inhibitor of TF-dependent pathway of blood coagulation, but previous studies failed to detect antigenic TFPI in cancer tissue. Recently, a second inhibitor of tissue factor dependent pathway, TFPI-2 (also known as placental protein 5 [PP5] or matrix-associated serine protease inhibitor [MSPI]), has been described. Information on the presence of TFPI-2 within the malignant tumor tissue still remains obscure, and thus the aim of this study was to evaluate the expression of TFPI-2 in loco in several different neoplasms. TFPI-2 expression was demonstrated by immu-nohistochemical procedures in neoplastic cells of laryngeal, breast, gastric, colon, pancreatic, renal and endometrial cancer, as well as glial neoplasms. The intensity of staining was not uniform, with higher intensity in more differentiated tumors. G3 breast, gastric, endometrial and colon cancer cells revealed populations of cells that were either TFPI-2 positive or negative. Gastric and renal cancer tissue exhibited the presence of TFPI-2 in tumor infiltrating macrophages. TFPI-2 was also observed in normal tissue of the breast, stomach, colon and pancreas. These data demonstrate that the expression of TFPI-2 diminishes with an increasing degree of malignancy, which may suggest a role for TFPI-2 in the maintenance of tumor stability and inhibition of the growth of neoplasms.

Keywords

Tissue factor pathway inhibitor-2 - tumor tissue - immunohisto-chemistry

• References

• 1 Sprecher CA, Kisiel W, Mathews S, Foster DC. Molecular cloning, expression, and partial characterization of a second tissue-factor-pathway-inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-7.
• 2 Peterson LC, Sprecher CA, Foster DC, Blum-berg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266-72.
• 3 Kisiel W, Sprecher CA, Foster DC. Evidence that a second tissue factor pathway inhibitor (TFPI-2) and placental protein 5 are equivalent. Blood 1994; 84: 4384-5.
• 4 Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, Misugi K, Umeda M, Miyazaki K. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 1994; 116: 939-42.
• 5 Bohn H, Winckler W. Isolierung und Charakterisierung des Plazenta-Proteins PP₅ . Arch Gynaek 1977; 223: 179-86.
• 6 Salem HAT, Obiekwe BC, Al-Ani ATM, Seppälä M, Chard T. Molecular heterogeneity of placental protein 5 (PP5) in late pregnancy serum and plasma: evidence for a heparin-PP5 polymer. Clin Chim Acta 1980; 107: 211-5.
• 7 Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 1995; 317: 311-4.
• 8 Rao CN, Peavey CL, Liu YY, Lapiere JC, Woodley DT. Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol 1995; 104: 379-83.
• 9 Rao CN, Reddy P, Liu Y. et al. Extracellular matrix-associated serine protease inhibitors (M_r 33,000, 31,000, 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 1996; 335: 82-92.
• 10 Miyagi Y, Yasumitsu H, Eki T. et al. Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Genomics 1996; 35: 267-8.
• 11 Seppälä M, Walström T, Bohn H. Circulating levels and tissue localization of placental protein five (PP5) in pregnancy and trophoblastic disease: absence of PP5 expression in the malignant trophoblast. Int J Cancer 1979; 24: 6-10.
• 12 Bützow R, Alfhan H, Stenman UH, Sulkkari AM, Bohn H, Seppälä M. Immunofluorimetric demonstration and quantification of placental protein 5 in the absence of pregnancy. Clin Chem 1988; 34: 1591-3.
• 13 Ortego J, Escribano J, Coca-Prados M. Gene expression of proteases and proteases inhibitors in the human ciliary epithelium and ODM-2 cells. Exp Eye Res 1997; 65: 289-99.
• 14 Udagawa K, Miyagi Y, Hirahara F. et al. Specific expression of PP5/TFPI-2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 1998; 19: 217-23.
• 15 Bützow R, Virtanen I, Seppälä M. et al. Monoclonal antibodies reacting with placental protein 5: use in radioimmunoassay, Western blot analysis, and immunohistochemistry. J Lab Clin Med 1988; 111: 249-56.
• 16 Ranta T, Siiteri JE, Koistinen R. et al. Human seminal plasma contains a protein that shares physiochemical and immunochemical properties with placental protein 5 from the human placenta. J Clin Endocrinol Metab 1981; 53: 1087-9.
• 17 Wahlström T, Bohn H, Seppälä M. Immuno-histochemical demonstration of placental protein 5 (PP5) – like material in the seminal vesicles and the ampullar part of vas deferens. Life Sci 1982; 31: 2723-5.
• 18 Seppälä M, Tenhunen A, Koskimies AI, Wahlström T, Koistinen R, Stenmam UH. Hyperstimulated human preovulatory follicular fluid contains placental protein 5 (PP5). Fertil Steril 1984; 41: 62-5.
• 19 Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998; 18: 40-6.
• 20 Deng FM, Ding M, Lavker RM, Sun TT. Urothelial function reconsidered: a role in urinary protein secretion. Proc Natl Acad Sci USA 2001; 98: 154-9.
• 21 Siiteri JE, Koistinen HAT, Salem HAT, Bohn H, Seppälä M. Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sci 1982; 30: 1885-91.
• 22 Meisser A, Bischof P, Bohn H. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen. Arch Gynecol 1985; 236: 197-201.
• 23 Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
• 24 Hillen HFP. Thrombosis in cancer patients. Ann Oncol 2000; 11 Suppl 3: 273-6.
• 25 Wojtukiewicz MZ, Rucinska M, Zacharski LR. et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001; 86: 1416-20.
• 26 Wojtukiewicz MZ, Rucinska M, Zimnoch L. et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000; 97: 335-42.
• 27 Shoji M, Hancock WW, Abe K, Micko C. et al. Activation of blood coagulation and angiogene-sis in cancer. Am J Pathol 1998; 152: 399-411.
• 28 Wojtukiewicz MZ, Zacharski LR, Memoli VA. et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989; 62: 1062-6.
• 29 Wojtukiewicz MZ, Zacharski LR, Rucinska M. et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost 1999; 82: 1659-62.
• 30 Wojtukiewicz MZ, Zacharski LR, Memoli VA. et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-82.
• 31 Wojtukiewicz MZ, Zacharski LR, Memoli VA. et al. Abnormal regulation of coagulation/ fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-5.
• 32 Wojtukiewicz MZ, Zacharski LR, Memoli VA. et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
• 33 Wojtukiewicz MZ, Tang TG, Ben-Josef E, Re-naud C, Walz DA, Honn KV. Solid tumor cells express functional “tethered ligand” thrombin receptor. Cancer Res 1995; 55: 698-704.
• 34 Wojtukiewicz MZ, Tang TG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, Mammen EF, Honn KV. Thrombin increases the metastatic potential of tumor cell. Int J Cancer 1993; 54: 793-806.
• 35 Wojtukiewicz MZ, Tang TG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbβ3 expression on the cell surface. Thromb Res 1992; 68: 233-45.
• 36 Even-Ram S, Uziely B, Cohen P. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4: 909-1006.
• 37 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
• 38 Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metast Rev 1992; 11: 249-66.
• 39 Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogene-sis. J Biol Chem 1999; 274: 23969-76.
• 40 Zhang Y, Deng Y, Luther T. et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
• 41 Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SA. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
• 42 Sato Y, Mukai K, Watanabe S, Goto M, Shim-osato Y. The AMeX method. The simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431-5.
• 43 Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immuno-peroxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
• 44 Callendar NS, Varki N, Rao LV. Immunohisto-chemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-201.
• 45 Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its corelation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-70.
• 46 Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M. Tissue factor expression in human colorectal carcinoma. Cancer 2000; 88: 295-301.
• 47 Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hem-atol 1996; 3: 379-84.
• 48 Rao CN, Lakka SS, Kin Y. et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human glio-mas. Clin Cancer Res 2001; 7: 570-6.
• 49 Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogene. FEBS Letters 2000; 481: 31-6.
• 50 Osella P, Carlson A, Wyandt H, Milunsky A. Cytogenetic studies of eight squamous cell carcinomas of the head and neck. Deletion of 7q, a possible primary chromosomal event. Cancer Genet Cytogenet 1992; 59: 73-8.
• 51 Atkin NB, Baker MC. Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogenet 1993; 67: 123-5.
• 52 Rowley JD, Mitelman F. Principles of molecular cell biology of cancer: chromosome abnormalities in human cancer and leukemia. In: Cancer. Principles and practice of oncology. DeVita VT, Hellman S, Rosenberg SA. (Eds.). J.B. Lippincott Company 1993; 4^th edition. pp. 67-91.
• 53 Jin M, Udagawa K, Miyagi E. et al. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001; 83: 325-33.
• 54 Lakka SS, Konduri SD, Mohanam S, Nicolson GL, Rao JS. In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin Exp Metastas 2000; 18: 239-44.
• 55 Konduri SD, Rao CN, Chandrasekar N. et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 2001; 20: 6938-45.
• 56 Rao CN, Cook B, Liu Y. et al. HT-1080 fibro-sarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 1998; 76: 749-56.
• 57 Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Cancer 2001; 18: 127-31.
• 58 Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL, Rao JS. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000; 18: 303-8.
• 59 Carroll V, Binder B. The role of the plasmino-gen activation system in cancer. Semin Thromb Hemost 1999; 25: 183-97.
• 60 Powell WC, Matrisian LM. Complex roles of matrix matalloproteinases in tumor progression. Curr Topics Microbiol Immunol 1996; 21: 1-21.
• 61 Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor. Biochem Biophys Res Com 1999; 255: 94-8.
• 62 Herman MP, Sukhova GK, Kisiel W. et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-26.
• 63 Neaud V, Hisaka T, Monvoisin A. et al. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J Biol Chem 2000; 275: 35565-9.
• 64 Tasiou A, Konduri SD, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Obeyesekere M, Rao JS. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Cancer 2001; 19: 591-7.
• 65 Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Sem Thromb Hemost 1999; 25: 173-82.